Genmab to shutter U.S. plant, cut 300 jobs

Denmark-based Genmab plans to cut some 300 jobs and sell off a U.S. manufacturing plant as it downgrades its expectations for 2009 sales for the second time; "cost pressures" in the pharma industry "will be permanent," CEO Lisa Drakeman said. Report 

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.